Antibody drug conjugates coming to primetime and new agents for breast cancer

Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma

Updates on triple negative breast cancer and immunotherapy

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy

Cancer advocacy and fundraising in Nigeria

ASCO 2024: Highlights and analysis

Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer